Imagine a world where #pancreaticcancer is detected early, where patients are guided to the best care from the moment of diagnosis, and where discoveries move from the lab to saving lives in years, not decades. That is the future PanCAN is building — by bringing together patients, families, researchers and clinicians to transform the future of this disease. 💜 Today at #PanCANPurpleStride, we launch our most ambitious effort yet, the $250 million All Together We Can campaign. Our vision: to make survival the expectation, not the exception, for the tens of thousands of people diagnosed with this disease every year. Why now? Because this disease remains the deadliest major cancer and the only one with a five-year survival rate below 20%. Because patients and their loved ones deserve more time, more treatment options and more effective screening strategies. Because our community knows that when we’re united in purpose and vision, we can achieve anything — and we’re ready to take on this next chapter. Learn more about how, over the next five years, the All Together We Can campaign will invest across three strategic pillars — forming a comprehensive approach to accelerate progress and improve survival for pancreatic cancer patients at 🔗 pcan.at/all-together-we-can.

Incredibly cool to bring these giants in KRAS biology and treatment together at @PanCAN Scientific Summit today and reminiscing over this 10-year-old video discussing whether KRAS will ever be druggable in #pancreaticcancer. Today, it finally is! 💜 piped.video/S-AqilU-T64?is=bHuG…

At a time of extraordinary progress in pancreatic cancer research and treatment, we’re grateful for the support of our PanCAN Scientific & Medical Affairs Industry Champions, including our newest Champions: @ClearNoteHealth, @Immunovia, Tango Therapeutics and returning Champions @AstellasUS and Ipsen. Together, we’re turning science into survival. 💜

Swapping my early-morning flight to Boston with an early-morning train to San Diego. Excited to attend @PanCAN Scientific Summit and @AACR #AACRpan26 and celebrate all the recent progress in #pancreaticcancer research and discuss the work ahead 💜

One of the most common conditions associated with pancreatic cancer may also be one of the least understood: Cancer cachexia. Sometimes known as wasting syndrome, cancer cachexia is the loss of 5% or more of body weight in six months. It is caused by many different factors that scientists are still trying to understand. It differs from weight loss because it is unintentional and happens even if the patient is still eating enough food to maintain their weight. Cancer cachexia is also different from weight loss because it affects muscles too. Instead of just losing weight from excess fat, cancer cachexia can cause significant muscle-wasting that can make patients feel weak and unable to withstand often intense cancer treatments. This muscle wasting can also include weakening of muscles of the heart and lungs, which makes early intervention important. This Cancer Cachexia Awareness Day, visit 🔗 pcan.at/po6j38 to learn more about this condition that affects more than 90% of people living with pancreatic cancer.

“My father was the rock of our family, and we all looked up to him.” When Nadine A.’s father, Eddie, was diagnosed with pancreatic cancer at just 46, her family knew very little about the disease. They found PanCAN while searching for information and support — and Nadine’s connection to the organization has continued ever since, even after her father’s passing. In 2003, she began volunteering in the Miami area, helping connect her community with information and resources about pancreatic cancer. She later stepped away while raising her children, then returned as a #PanCANvolunteer leader about four years ago. Today, she serves as chair of the PanCAN Miami Affiliate. One memory from those early days has stayed with her. When PanCAN sent her a box filled with educational materials and purple items to share in her community, she showed it to her father. “He said, ‘Wow, that’s hope in a box.’” For Nadine, volunteering has become a way to honor her father, give back to her community and show her children the value of helping others. “I feel like I’ve gained more from volunteering than I’ve put in.” Her whole family has been part of the journey — from helping at events when her children were young to having extended family members contribute their time and support. “It’s a very good feeling to work together for a cause that’s so important to us.” Read Nadine’s story and learn more about the impact of volunteering with PanCAN at 🔗 pcan.at/m9mjd5uq.

🔬

To our invited Community for Progress members, let me know in the comments if I’ll see you in California! Together, we can turn science into survival. 💜

This year, unprecedented progress in research is creating a renewed sense of urgency and opportunity. @PanCAN is bringing leaders in pancreatic cancer research together to discuss where we are, where we’re headed and how we can accelerate progress for patients and families.

I’m headed to San Diego today for @PanCAN’s Scientific Summit 2026, ahead of #AACRpan26 later this week!

#PanCANPurpleStride 2027 is happening Saturday, April 24, and we want our Team Captains back — and looking good! 💜 Register as a Team Captain, raise $50+ toward your personal fundraising goal by Friday, October 9, and you’ll earn a limited-edition Team Captain hat, perfect for wearing at PurpleStride! Visit 🔗 purplestride.org to register today!

Happy first day of fall, PanCAN community. 💜

On this day five years ago, actor Willie Garson died at age 57 from pancreatic cancer. Today, we remember Willie and honor everyone whose life has been affected by pancreatic cancer. 💜 In 2026, an estimated 67,530 people in the U.S. will be diagnosed with pancreatic cancer, and approximately 52,740 will die from the disease. Learn more about pancreatic cancer and how PanCAN is turning science into survival at 🔗 pancan.org. 📷: E! News

Join PanCAN Chief Scientific and Medical Officer Anna Berkenblit, MD, MMSc, for a Right Track Live virtual event focused on helping patients, caregivers and loved ones better understand pancreatic neuroendocrine tumors (also known as PNETs) and what recent advances mean for those affected by the disease. We will bring together leading PNET experts to share the latest information, answer common questions and provide practical insights into diagnosis, treatment and ongoing research. You’ll learn more about: 💜 How PNETs differ from the most common type of pancreatic cancer, including how they develop and why care often requires a specialized treatment approach. ⚠️ Common signs and symptoms that are unique to PNETs, including symptoms related to hormone changes that may be overlooked. 💊 Current treatment approaches and what patients should know about available targeted therapies and clinical trials. 🔬 Advances in PNET research and what it means for patients, including how to prepare for informed conversations with healthcare providers about treatment options and goals of care. Save your seat at 🔗 pcan.at/RightTrackLive.

Put your purple knowledge to the test! Which shade is the official PanCAN purple? 💜

PanCAN President and CEO @JulieFleshman recently joined @NCODAorg on their PQI Podcast, sharing the personal journey that brought her to PanCAN 26 years ago after losing her father to pancreatic cancer. She reflects on how far we’ve come — from the state of pancreatic cancer research and treatment then to the progress giving our community more reasons for hope today. Listen to the conversation at 🔗 ncoda.org/resource/keep-marc….

Six years ago today, U.S. Supreme Court Justice Ruth Bader Ginsburg died at age 87 from complications of metastatic pancreatic cancer. Ginsburg was first diagnosed with pancreatic cancer in 2009, when doctors discovered a small malignant tumor in her pancreas. She underwent surgery to remove part of her pancreas and her spleen. In 2019, a malignant tumor was detected in her pancreas and treated with radiation. At the time, the Supreme Court announced there was “no evidence of disease elsewhere in the body.” Then in 2020, cancer recurred. After lesions were detected on her liver, Ginsburg began chemotherapy to treat the recurrence. She died on September 18, 2020, from complications of metastatic pancreatic cancer. Today, we remember Justice Ginsburg and honor everyone whose life has been affected by pancreatic cancer. 💜 More than 67,000 people in the U.S. will be diagnosed with pancreatic cancer this year. Visit 🔗 pancan.org to learn more about the disease and how PanCAN can help. 📷: AP News

PanCAN President and CEO @JulieFleshman shares, "Yesterday, I spent the day on Capitol Hill meeting with members of Congress and their staff to advocate for continued federal investment in pancreatic cancer research. As Congress works toward a final FY27 spending package, we emphasized the importance of robust funding for the NIH and NCI, as well as continued investment in the Pancreatic Cancer Research Program at the DoD. We also took a moment to acknowledge that years of federally funded research helped lay the foundation for breakthroughs like the FDA’s recent approval of RASONQUE, the first targeted RAS inhibitor approved for pancreatic cancer. This is an important moment for our community — and a powerful reminder of what sustained investment in research can accomplish. But this is not the time to slow down. We need to build on this momentum, continue investing in the science and make sure the next breakthrough reaches patients. I’m grateful to the members of Congress who continue to champion pancreatic cancer research, and I’ll keep working alongside our advocates to make sure pancreatic cancer remains a priority." Learn more about our advocacy in action at 🔗 pcan.at/advocate.

As part of our commitment to accelerate breakthrough research through the All Together We Can campaign, PanCAN announces nearly $3 million in grants that support cutting-edge science and fill critical gaps in the pancreatic cancer funding landscape. 🔬 The four Catalyst Research Awards, totaling nearly $2 million, are aimed at harnessing the power of tumor tissue, blood samples and patient data to accelerate the development of new treatments for patients with metastatic pancreatic cancer. This unparalleled resource — collected from participants in the PanCAN Precision Promise adaptive clinical trial platform — fills a critical gap in the research landscape. We’re providing researchers the materials they need to identify biomarkers of treatment response and resistance that can be targeted for more effective therapies. The goal is to drive discovery, inform trial design and bring us closer to a future where precision medicine is a reality for every person faced with this disease. Data generated from the awards will be integrated into PanCAN’s SPARK Research Data Platform and made available for future use by the pancreatic cancer research community, multiplying the value of these projects. Our eight Research Recovery Grants, totaling $1 million, fill the gap to rescue science that was otherwise going to go unfunded due to federal funding uncertainties. We are strategically targeting a breadth of topics and scientists at various career stages. These grants support researchers as the field reaches a critical turning point: With more RAS-targeting therapies in the pipeline than ever before, our goal is to keep the momentum we need to deliver breakthroughs as soon as possible for patients and families facing this disease. Meet this year’s Catalyst Research Award and Research Recovery Grant recipients at 🔗 pcan.at/bs58394r.

We are pleased to announce @AndrewWaters, PhD, from @UC_Health, as a 2026 PanCAN grant recipient, made possible by generous support from PanCAN donors. 🔬 Dr. Waters will lead a research project titled “Determining the role of KSR in mediating resistance to KRAS inhibition in PDAC.” This grant is in memory of Terry Newendrop. Read more about Dr. Waters’s project at 🔗 pcan.at/bs58394r.

We are pleased to announce Kazuki Sugahara, MD, PhD, from @ColumbiaMed University, as a 2026 PanCAN grant recipient, made possible by generous support from PanCAN donors. 🔬 Dr. Sugahara will lead a research project titled “Tumor-penetrating stromal modification of ß5 integrin-rich pancreatic cancer.” This grant is supported by an anonymous donor. Read more about Dr. Sugahara’s project at 🔗 pcan.at/bs58394r.